Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/18/09 on Power3 Medical Products, Inc. (OTC:PWRM). Shares of the company finished the day at $0.129, up 69.74% from the opening bell on heavy buying pressure. The spark which ignited the rise in share price is being speculated as being attributed due to the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 19-21, 2009, of which Power3 Medical will be attending. Excitement over the company is building, as they will now be exposed to over 50,000 scientists worldwide. Volume at the end of day was 21.62M as compared to the daily average of 2.6M.

About Power3 Medical Products, Inc.

…

Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/18/09 on Power3 Medical Products, Inc. (OTC:PWRM). Shares of the company finished the day at $0.129, up 69.74% from the opening bell on heavy buying pressure. The spark which ignited the rise in share price is being speculated as being attributed due to the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 19-21, 2009, of which Power3 Medical will be attending. Excitement over the company is building, as they will now be exposed to over 50,000 scientists worldwide. Volume at the end of day was 21.62M as compared to the daily average of 2.6M.

About Power3 Medical Products, Inc.

…

On Monday morning, the Food and Drug Administration panel approved Arzerra, a leukemia treatment that will be marketed and commercialized by GlaxoSmithKline Plc (ADR) (NYSE:GSK). As per the announcement made by the GSK executives, Arzerra is for those patients who have failed to respond to other therapies that cure leukemia. This new drug marketed by GSK was originally developed by GlaxoSmithKline and Genmab A/S, a Danish company. The drug is designed to treat patients with chronic lymphocytic leukemia also known as CLL and for those whose disease has progressed despite previous treatments with other cancer drugs.

GSK is a global healthcare company that is more into the creation and development, manufacturing and marketing of various pharmaceutical products including vaccines and over the counter medicines and other health related

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Tuesday October 27, 2009, are:

**************************************************************

GSK, GlaxoSmithKline plc

GSK, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter medicines, and health related consumer products. GSK operates in two segments, Pharmaceutical and Consumer Healthcare.

** The Food and Drug Administration Monday approved Arzerra, a leukemia treatment that will be marketed by GSK for patients who have failed to respond to other therapies.

More about GSK at www.gsk.com

**************************************************************

EVRN, Everock Inc., EVRN.PK

EVRN produces a line of all-natural gourmet vegetable dips and sandwich spreads marketed under the Nature’s Peak brand.

Both

...

Genzyme Corporation (GENZ) recently reported positive results from a randomized phase III study that was conducted with Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) in relapsed or refractory chronic lymphocytic leukemia (CLL) patients.  The company reported that patients treated with Campath and Fludara (FluCAM) experienced a significant improvement in progression free survival (PFS), compared to patients receiving only Fludara. The study was designed to detect at least a 50% overall improvement in PFS in the FluCAM arm compared to the Fludara arm.  Although the company did not disclose full results, Genzyme announced that the trial’s independent data safety monitoring board, in a pre-planned interim analysis, determined that the study achieved its primary endpoint and recommended early closure of the trial.  We look forward to detailed results from the study in December at the American Society of Hematology. Impressive PFS results could help the combination ...

Power3 Medical Products, Inc.

(Public, OTC:PWRM)

The following company analysis has been contributed by a StocksHaven Investments affiliate and member, Michael Sklar. He has been studying the markets for several years now with a focus in undiscovered Bio-Pharm companies.

About

Power3 Medical Products, Inc. (Power3) is primarily engaged in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease. In the area of neurodegenerative diseases and breast cancer, Power3 has completed research and clinical validation studies involving over 1,500 patient samples. Power3 uses biostatistical analysis to monitor appropriate panels of biomarkers for diagnostic sensitivity and specificity for disease, normal and disease controls. By testing patient body fluids and tissues, including blood serum (for breast cancer and neurodegenerative diseases), and bone marrow aspirates (for leukemia patients), the Company

...

BSX, Boston Scientific Corporation

PWRM, Power 3 Medical Products Inc, PWRM.OB

PennyOmega.com Watch List!

PennyOmega.com Watch List ! for Tuesday July 21, 2009

Our Picks at PennyOmega.com for Tuesday July 21, 2009 are:

**************************************************************

BSX, Boston Scientific Corporation

BSX operates as a developer, manufacturer, and marketer of medical devices used in various interventional medical specialties worldwide.

BSX’s products help physicians and other medical professionals improve the patients quality of life by providing alternatives to surgery.

*To consider about BSX

Today, after Closing Bell, BSX announced financial results for the second quarter ended June 30, 2009.

Net sales for the second quarter of 2009 were $2.074 billion, as compared to net sales of $2.024 billion for the second

...

Access Pharmaceuticals, Inc. announced earlier this morning new preclinical data demonstrating that thiarabine, one of the company’s advanced drug delivery technologies, shows extraordinary efficacy in preventing and treating rheumatoid arthritis (RA). In a well-established animal model for RA, a remarkable restoration of joint structure was observed. The studies were conducted at Wayne State University School of Medicine and at Southern Research Institute.

According to the press release, thiarabine treatment resulted in a broad inhibition of disease pathology, with reduction of both inflammatory and erosive disease parameters, as well as protection from loss of cartilage matrix proteins. When used as a preventative treatment, thiarabine blocked the development of joint disease at the 60 mg/kg/day dose level and exhibited a considerable reduction in disease incidence and severity at 20 mg/kg/day.

Perhaps even more exciting, in a therapeutic study comparing thiarabine to methotrexate, a commonly used clinical drug for RA treatment, high resolution

...

Since I last wrote about Access Pharma [ACCP: 0.00, N/A (N/A)] two weeks ago as a cancer biotech call option trade, the Company has issued two updates on its clinical development pipeline and two updates for MuGard – which is an oral rinse product for the management of a common side effect of many cancer therapies, mucositis. In late May, Access announced that MuGard was launched in Germany, Italy, UK, Greece, and the Nordic countries by its European commercial partner, SpePharm, with expected launches in North America, Asia, and other regions slated for later this year. On 6/10/09, ACCP.OB also announced that the Company received issue notifications from the United States Patent and Trademark Office for two US patents (numbers 7,544,348 and 7,547,433).

A video presentation is available at ProActiveNewsRoom.com for MuGard, in addition to more information and links at the landing page

...

The cancer biotech space has attracted the interest of investors, traders, and diversified healthcare giants this year with Johnson & Johnson [JNJ: 55.50, +0.34 (+0.62%)] announcing a $1B cash tender offer for Cougar Biotech [CGRB: 42.87, -0.12 (-0.28%)] last week and Roche’s [ROG: 17.67, +0.61 (+3.58%)] [RHHBY: 0.00, N/A (N/A)] mega-deal to acquire full control of Genentech earlier this year. In addition, positive clinical trial results for Dendreon’s [DNDN: 23.2099, +0.5399 (+2.38%)] Provenge and stock price turnarounds from the brink of zero at Cell Therapeutics [CTIC: 1.60, +0.17 (+11.89%)] have fueled interest in the small and micro-cap cancer bio-pharma space among investors and traders looking for the next big trade.

Access Pharma [ACCP: 0.00, N/A (N/A)] is an emerging bio-pharma company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to

...